The core activity of Linkster Therapeutics is the development of precise medicines through the application of innovative technologies such as Flycode and Sybody. The company focuses on the research and development of antibodies for targeted therapy, particularly for the treatment of diseases that require a targeted effect on specific cells or tissues. This includes the development of antibodies for targeted delivery in specific tissues, the creation of conformation-specific antibody candidates against cell surface targets, and the application of translational antibody engineering technology based on Flycode peptide barcodes.